Pazopanib as third-line therapy for metastatic renal cell carcinoma: Clinical efficacy and temporal analysis of cytokine profile

被引：0
|
作者：
Pal, Sumanta K. [1 ]
Hossain, Dewan Md Sakib [1 ]
Zhang, Qifang [1 ]
Gao, Chan [1 ]
Jones, Jeremy O. [1 ]
Frankel, Paul H. [1 ]
Figlin, Robert A. [2 ]
Kortylewski, Marcin [1 ]
机构：
[1] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT334
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
    Grassi, Paolo
    Procopio, Giuseppe
    Ratta, Raffaele
    Porcu, Luca
    Martinetti, Antonia
    Mennitto, Alessia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [32] Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Grassi, Paolo
    Verzoni, Elena
    Ratta, Raffaele
    Porcu, Luca
    Prisciandaro, Michele
    Mennitto, Alessia
    Calareso, Giuseppina
    de Braud, Filippo
    Procopio, Giuseppe
    DRUGS IN R&D, 2017, 17 (03) : 461 - 467
  • [33] Nursing Considerations With Pazopanib Therapy: Focus on Metastatic Renal Cell Carcinoma
    Bourdeanu, Laura
    Twardowski, Przemyslaw
    Pal, Sumanta Kumar
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2011, 15 (05) : 513 - 517
  • [34] Outcomes of unselected patients with metastatic renal cell carcinoma treated with front-line pazopanib therapy
    Matrana, M.
    Shetty, A.
    Teegavarapu, R.
    Kalra, S.
    Xiao, L.
    Atkinson, B.
    Corn, P.
    Jonasch, E.
    Tannir, N. M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S668 - S669
  • [35] CYTOKINE THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    OTTO, T
    GOEPEL, M
    LUBOLDT, HJ
    RUBBEN, H
    UROLOGE-AUSGABE A, 1995, 34 (03): : 200 - 203
  • [36] Efficacy and safety of regorafenib as third-line therapy in metastatic colorectal cancer: An indirect meta-analysis
    Wu, Yinying
    Fan, Yangwei
    Dong, Dan Feng
    Dong, Xuyuan
    Hu, Yuan
    Shi, Yu
    Jing, Jiayu
    Li, En Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [37] First line pazopanib in poor risk patients with metastatic renal cell carcinoma
    Staehler, M.
    Panic, A.
    Merling, M.
    Vannier, C.
    Herrmann, E.
    Hogrefe, C.
    Potthoff, K.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 203 - 203
  • [38] Efficacy and safety of third- and fourth-line targeted therapy in Japanese patients with metastatic renal cell carcinoma: A retrospective analysis
    Takahito, Negishi
    Kei, Nagase
    Hidenori, Iwai
    Nobuki, Furubayashi
    Kenichi, Taguchi
    Motonobu, Nakamura
    INDIAN JOURNAL OF UROLOGY, 2018, 34 (02) : 127 - 132
  • [39] Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Editorial Comment
    Marshall, Fray F.
    JOURNAL OF UROLOGY, 2010, 184 (04): : 1303 - 1303
  • [40] Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma
    Iacovelli, Roberto
    Santini, Daniele
    Rizzo, Mimma
    Felici, Alessandra
    Santoni, Matteo
    Verzoni, Elena
    Masini, Cristina
    Massari, Francesco
    Calvani, Nicola
    Mosca, Alessandra
    Procopio, Giuseppe
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (7-8): : 263 - 267
12345